Scribe Therapeutics

Epigenetic CRISPR company silencing target genes through chromatin modification rather than cutting DNA. Filed with the SEC to go public on the Nasdaq under ticker SCTX — the first gene editing IPO attempt since Metagenomi in 2024. Has banked $120 million in venture funding and pharma collaborations with Biogen, Sanofi, and Eli Lilly subsidiary Prevail Medicines. Lead asset STX-1150, a single-dose epigenetic silencing treatment targeting PCSK9 for high cholesterol, entered the clinic in June 2026.